instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the dosage of drug 'HALOPERIDOL'? | Clozapine Intoxication in a Patient on Chronic Use With a Short-Term Noncompliance.
Clozapine has been associated with various adverse effects at both subtherapeutic and standard doses. These adverse effects are most commonly seen during the initiation of therapy in treatment-naïve patients. However, reports of intoxic... | 5 mg (milligrams). | DrugDosage | CC BY | 34430174 | 19,792,886 | 2021-07 |
What was the outcome of reaction 'Dysarthria'? | Clozapine Intoxication in a Patient on Chronic Use With a Short-Term Noncompliance.
Clozapine has been associated with various adverse effects at both subtherapeutic and standard doses. These adverse effects are most commonly seen during the initiation of therapy in treatment-naïve patients. However, reports of intoxic... | Recovered | ReactionOutcome | CC BY | 34430174 | 19,792,886 | 2021-07 |
What was the outcome of reaction 'Mental status changes'? | Clozapine Intoxication in a Patient on Chronic Use With a Short-Term Noncompliance.
Clozapine has been associated with various adverse effects at both subtherapeutic and standard doses. These adverse effects are most commonly seen during the initiation of therapy in treatment-naïve patients. However, reports of intoxic... | Recovered | ReactionOutcome | CC BY | 34430174 | 19,792,886 | 2021-07 |
What was the outcome of reaction 'Somnolence'? | Clozapine Intoxication in a Patient on Chronic Use With a Short-Term Noncompliance.
Clozapine has been associated with various adverse effects at both subtherapeutic and standard doses. These adverse effects are most commonly seen during the initiation of therapy in treatment-naïve patients. However, reports of intoxic... | Recovered | ReactionOutcome | CC BY | 34430174 | 19,792,886 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal disorder'. | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | METHYLPREDNISOLONE, RITUXIMAB, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 34430206 | 20,194,499 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal necrosis'. | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | COLISTIN, GANCICLOVIR, METHYLPREDNISOLONE, RITUXIMAB, TIGECYCLINE, TOCILIZUMAB, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY-NC-ND | 34430206 | 19,860,888 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | RITUXIMAB, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 34430206 | 19,794,234 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | COLISTIN, GANCICLOVIR, METHYLPREDNISOLONE, RITUXIMAB, TIGECYCLINE, TOCILIZUMAB, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY-NC-ND | 34430206 | 19,860,888 | 2021 |
What was the administration route of drug 'GANCICLOVIR'? | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34430206 | 19,860,888 | 2021 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34430206 | 20,165,784 | 2021 |
What was the administration route of drug 'RITUXIMAB'? | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34430206 | 19,794,234 | 2021 |
What was the administration route of drug 'TOCILIZUMAB'? | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34430206 | 20,165,784 | 2021 |
What was the outcome of reaction 'Pneumonia'? | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | Fatal | ReactionOutcome | CC BY-NC-ND | 34430206 | 19,794,234 | 2021 |
What was the outcome of reaction 'Respiratory failure'? | Passage of intestinal casts-An unusual presentation of Cytomegalovirus enterocolitis.
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizu... | Fatal | ReactionOutcome | CC BY-NC-ND | 34430206 | 19,794,234 | 2021 |
What is the weight of the patient? | Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics.
To present a case series that illustrates real-world use of pegvaliase based on the initial experiences of US healthcare providers.
Sixteen healthcare providers from 14 centers across the US with substantial clinical ... | 71 kg. | Weight | CC BY-NC-ND | 34430209 | 20,922,445 | 2021-09 |
What was the administration route of drug 'DIPHENHYDRAMINE'? | Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics.
To present a case series that illustrates real-world use of pegvaliase based on the initial experiences of US healthcare providers.
Sixteen healthcare providers from 14 centers across the US with substantial clinical ... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34430209 | 20,788,132 | 2021-09 |
What was the administration route of drug 'LORATADINE'? | Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics.
To present a case series that illustrates real-world use of pegvaliase based on the initial experiences of US healthcare providers.
Sixteen healthcare providers from 14 centers across the US with substantial clinical ... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34430209 | 20,788,132 | 2021-09 |
What was the administration route of drug 'RANITIDINE'? | Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics.
To present a case series that illustrates real-world use of pegvaliase based on the initial experiences of US healthcare providers.
Sixteen healthcare providers from 14 centers across the US with substantial clinical ... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34430209 | 20,788,132 | 2021-09 |
What was the dosage of drug 'CETIRIZINE HYDROCHLORIDE'? | Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics.
To present a case series that illustrates real-world use of pegvaliase based on the initial experiences of US healthcare providers.
Sixteen healthcare providers from 14 centers across the US with substantial clinical ... | UNK, Q.H.S. | DrugDosageText | CC BY-NC-ND | 34430209 | 20,922,445 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bone pain'. | Macro-Ck type 2 syndrome in prostate adenocarcinoma: Case report and review article.
A 67-year-old male had prostate adenocarcinoma with liver, bone metastases, iliac lymph nodes invasion ever receive hormone and chemotherapy. He was presented to our emergency department with acute onset of mild dizziness and shortness... | DOCETAXEL, ENZALUTAMIDE, LEUPROLIDE ACETATE | DrugsGivenReaction | CC BY-NC-ND | 34430214 | 19,986,347 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic failure'. | Macro-Ck type 2 syndrome in prostate adenocarcinoma: Case report and review article.
A 67-year-old male had prostate adenocarcinoma with liver, bone metastases, iliac lymph nodes invasion ever receive hormone and chemotherapy. He was presented to our emergency department with acute onset of mild dizziness and shortness... | DOCETAXEL, ENZALUTAMIDE, LEUPROLIDE ACETATE | DrugsGivenReaction | CC BY-NC-ND | 34430214 | 19,986,347 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Macroenzyme creatine kinase'. | Macro-Ck type 2 syndrome in prostate adenocarcinoma: Case report and review article.
A 67-year-old male had prostate adenocarcinoma with liver, bone metastases, iliac lymph nodes invasion ever receive hormone and chemotherapy. He was presented to our emergency department with acute onset of mild dizziness and shortness... | DOCETAXEL, ENZALUTAMIDE, LEUPROLIDE ACETATE | DrugsGivenReaction | CC BY-NC-ND | 34430214 | 19,986,347 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to liver'. | Macro-Ck type 2 syndrome in prostate adenocarcinoma: Case report and review article.
A 67-year-old male had prostate adenocarcinoma with liver, bone metastases, iliac lymph nodes invasion ever receive hormone and chemotherapy. He was presented to our emergency department with acute onset of mild dizziness and shortness... | DOCETAXEL, ENZALUTAMIDE, LEUPROLIDE ACETATE | DrugsGivenReaction | CC BY-NC-ND | 34430214 | 19,986,347 | 2021-11 |
What was the administration route of drug 'LEUPROLIDE ACETATE'? | Macro-Ck type 2 syndrome in prostate adenocarcinoma: Case report and review article.
A 67-year-old male had prostate adenocarcinoma with liver, bone metastases, iliac lymph nodes invasion ever receive hormone and chemotherapy. He was presented to our emergency department with acute onset of mild dizziness and shortness... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-ND | 34430214 | 19,986,347 | 2021-11 |
What was the dosage of drug 'DOCETAXEL'? | Macro-Ck type 2 syndrome in prostate adenocarcinoma: Case report and review article.
A 67-year-old male had prostate adenocarcinoma with liver, bone metastases, iliac lymph nodes invasion ever receive hormone and chemotherapy. He was presented to our emergency department with acute onset of mild dizziness and shortness... | 130 MG/M2, THREE WEEKLY | DrugDosageText | CC BY-NC-ND | 34430214 | 19,986,347 | 2021-11 |
What was the outcome of reaction 'Hepatic failure'? | Macro-Ck type 2 syndrome in prostate adenocarcinoma: Case report and review article.
A 67-year-old male had prostate adenocarcinoma with liver, bone metastases, iliac lymph nodes invasion ever receive hormone and chemotherapy. He was presented to our emergency department with acute onset of mild dizziness and shortness... | Fatal | ReactionOutcome | CC BY-NC-ND | 34430214 | 19,986,347 | 2021-11 |
What was the outcome of reaction 'Metastases to liver'? | Macro-Ck type 2 syndrome in prostate adenocarcinoma: Case report and review article.
A 67-year-old male had prostate adenocarcinoma with liver, bone metastases, iliac lymph nodes invasion ever receive hormone and chemotherapy. He was presented to our emergency department with acute onset of mild dizziness and shortness... | Fatal | ReactionOutcome | CC BY-NC-ND | 34430214 | 19,986,347 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Enterocolitis'. | Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Atezolizumab combined with bevacizumab plus platinum-based chemotherapy is a standard treatment for advanced non-squamous non-small-cell lung cancer (nsNSCLC). We aimed to de... | BEVACIZUMAB, CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY-NC-ND | 34430347 | 19,707,442 | 2021-07 |
What was the dosage of drug 'BEVACIZUMAB'? | Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Atezolizumab combined with bevacizumab plus platinum-based chemotherapy is a standard treatment for advanced non-squamous non-small-cell lung cancer (nsNSCLC). We aimed to de... | 15 MG/KG, CYCLIC (ON DAY 1) | DrugDosageText | CC BY-NC-ND | 34430347 | 19,707,442 | 2021-07 |
What was the dosage of drug 'CARBOPLATIN'? | Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Atezolizumab combined with bevacizumab plus platinum-based chemotherapy is a standard treatment for advanced non-squamous non-small-cell lung cancer (nsNSCLC). We aimed to de... | AREA UNDER THE CONCENTRATIONTIME CURVE OF 6 MG/ML/MIN, CYCLIC (ON DAY 1) | DrugDosageText | CC BY-NC-ND | 34430347 | 19,707,442 | 2021-07 |
What was the dosage of drug 'PACLITAXEL'? | Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Atezolizumab combined with bevacizumab plus platinum-based chemotherapy is a standard treatment for advanced non-squamous non-small-cell lung cancer (nsNSCLC). We aimed to de... | 200 MG/M2, CYCLIC (ON DAY 1) | DrugDosageText | CC BY-NC-ND | 34430347 | 19,707,442 | 2021-07 |
What was the outcome of reaction 'Enterocolitis'? | Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Atezolizumab combined with bevacizumab plus platinum-based chemotherapy is a standard treatment for advanced non-squamous non-small-cell lung cancer (nsNSCLC). We aimed to de... | Fatal | ReactionOutcome | CC BY-NC-ND | 34430347 | 19,707,442 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Progressive pseudorheumatoid dysplasia: a case series report.
rogressive pseudorheumatoid dysplasia (PPRD) is a rare autosomal-recessive, noninflammatory arthropathy. Several cases have been reported worldwide; however, diagnosis remains challenging. Three unrelated children with PPRD were retrospectively studied. All ... | SOMATROPIN | DrugsGivenReaction | CC BY-NC-ND | 34430442 | 19,739,948 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gait disturbance'. | Progressive pseudorheumatoid dysplasia: a case series report.
rogressive pseudorheumatoid dysplasia (PPRD) is a rare autosomal-recessive, noninflammatory arthropathy. Several cases have been reported worldwide; however, diagnosis remains challenging. Three unrelated children with PPRD were retrospectively studied. All ... | SOMATROPIN | DrugsGivenReaction | CC BY-NC-ND | 34430442 | 19,739,948 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Progressive pseudorheumatoid dysplasia: a case series report.
rogressive pseudorheumatoid dysplasia (PPRD) is a rare autosomal-recessive, noninflammatory arthropathy. Several cases have been reported worldwide; however, diagnosis remains challenging. Three unrelated children with PPRD were retrospectively studied. All ... | SOMATROPIN | DrugsGivenReaction | CC BY-NC-ND | 34430442 | 19,736,479 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Spondyloepiphyseal dysplasia'. | Progressive pseudorheumatoid dysplasia: a case series report.
rogressive pseudorheumatoid dysplasia (PPRD) is a rare autosomal-recessive, noninflammatory arthropathy. Several cases have been reported worldwide; however, diagnosis remains challenging. Three unrelated children with PPRD were retrospectively studied. All ... | SOMATROPIN | DrugsGivenReaction | CC BY-NC-ND | 34430442 | 19,736,479 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal disorder'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myelosuppression'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Palmar-plantar erythrodysaesthesia syndrome'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Platelet count decreased'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | CAPECITABINE, LOBAPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
What was the dosage of drug 'CAPECITABINE'? | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | FROM DAY 1 TO DAY 14 | DrugDosageText | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
What was the dosage of drug 'LOBAPLATIN'? | A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer... | FOR 3 WEEKS AS 1 CYCLE | DrugDosageText | CC BY-NC-ND | 34430592 | 19,702,313 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abnormal dreams'. | Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.
We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/teno... | EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY-NC-ND | 34430674 | 20,090,380 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.
We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/teno... | EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY-NC-ND | 34430674 | 20,090,380 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sleep disorder'. | Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.
We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/teno... | EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY-NC-ND | 34430674 | 20,090,380 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Weight decreased'. | Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.
We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/teno... | EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY-NC-ND | 34430674 | 20,090,380 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma.
•Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer.•KRAS mutations are characteristic in patients with endometrial MLA.•We r... | LENVATINIB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 34430690 | 19,785,254 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma.
•Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer.•KRAS mutations are characteristic in patients with endometrial MLA.•We r... | LENVATINIB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 34430690 | 19,785,254 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myalgia'. | Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma.
•Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer.•KRAS mutations are characteristic in patients with endometrial MLA.•We r... | LENVATINIB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 34430690 | 19,785,255 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma.
•Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer.•KRAS mutations are characteristic in patients with endometrial MLA.•We r... | LENVATINIB MESYLATE, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 34430690 | 19,772,582 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma.
•Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer.•KRAS mutations are characteristic in patients with endometrial MLA.•We r... | CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY-NC-ND | 34430690 | 20,203,762 | 2021-08 |
What was the administration route of drug 'LENVATINIB'? | Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma.
•Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer.•KRAS mutations are characteristic in patients with endometrial MLA.•We r... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34430690 | 19,785,254 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Bail-out treatment of pulmonary embolism using a large-bore aspiration mechanical thrombectomy device.
We report on the first pulmonary embolism treatment via the large-bore aspiration mechanical thrombectomy device (Inari FlowTriever®) outside the USA, in a resuscitated patient on veno-arterial extracorporeal membrane... | ALTEPLASE, HEPARIN SODIUM | DrugsGivenReaction | CC BY-NC-ND | 34431236 | 20,207,722 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Heparin-induced thrombocytopenia'. | Bail-out treatment of pulmonary embolism using a large-bore aspiration mechanical thrombectomy device.
We report on the first pulmonary embolism treatment via the large-bore aspiration mechanical thrombectomy device (Inari FlowTriever®) outside the USA, in a resuscitated patient on veno-arterial extracorporeal membrane... | ALTEPLASE, HEPARIN SODIUM | DrugsGivenReaction | CC BY-NC-ND | 34431236 | 20,207,722 | 2021-10 |
What was the dosage of drug 'ALTEPLASE'? | Bail-out treatment of pulmonary embolism using a large-bore aspiration mechanical thrombectomy device.
We report on the first pulmonary embolism treatment via the large-bore aspiration mechanical thrombectomy device (Inari FlowTriever®) outside the USA, in a resuscitated patient on veno-arterial extracorporeal membrane... | 100 mg (milligrams). | DrugDosage | CC BY-NC-ND | 34431236 | 20,207,722 | 2021-10 |
What was the outcome of reaction 'Heparin-induced thrombocytopenia'? | Bail-out treatment of pulmonary embolism using a large-bore aspiration mechanical thrombectomy device.
We report on the first pulmonary embolism treatment via the large-bore aspiration mechanical thrombectomy device (Inari FlowTriever®) outside the USA, in a resuscitated patient on veno-arterial extracorporeal membrane... | Recovered | ReactionOutcome | CC BY-NC-ND | 34431236 | 20,207,722 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemorrhage'. | Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study
This study aimed to evaluate systemic thrombolysis experiences with recombinant tissue plasminogen activator (rtPA).
Retrospective data were collected from 13 Turkish pediatric hematology centers. The d... | ALTEPLASE | DrugsGivenReaction | CC BY | 34431642 | 19,912,691 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study
This study aimed to evaluate systemic thrombolysis experiences with recombinant tissue plasminogen activator (rtPA).
Retrospective data were collected from 13 Turkish pediatric hematology centers. The d... | ALTEPLASE | DrugsGivenReaction | CC BY | 34431642 | 19,912,691 | 2021-12-07 |
What was the administration route of drug 'ALTEPLASE'? | Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study
This study aimed to evaluate systemic thrombolysis experiences with recombinant tissue plasminogen activator (rtPA).
Retrospective data were collected from 13 Turkish pediatric hematology centers. The d... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34431642 | 19,912,691 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Enterococcal bacteraemia'. | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34431691 | 20,113,631 | 2021-08-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Focal segmental glomerulosclerosis'. | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | MYCOPHENOLIC ACID, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34431691 | 20,089,078 | 2021-08-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | MYCOPHENOLIC ACID, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34431691 | 20,067,933 | 2021-08-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Transplant rejection'. | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | MYCOPHENOLIC ACID, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34431691 | 20,089,078 | 2021-08-25 |
What was the outcome of reaction 'COVID-19 pneumonia'? | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | Fatal | ReactionOutcome | CC BY | 34431691 | 20,059,685 | 2021-08-25 |
What was the outcome of reaction 'COVID-19'? | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | Recovered | ReactionOutcome | CC BY | 34431691 | 20,013,384 | 2021-08-25 |
What was the outcome of reaction 'Lymphopenia'? | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | Recovering | ReactionOutcome | CC BY | 34431691 | 20,013,384 | 2021-08-25 |
What was the outcome of reaction 'Respiratory failure'? | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | Fatal | ReactionOutcome | CC BY | 34431691 | 20,059,685 | 2021-08-25 |
What was the outcome of reaction 'Septic shock'? | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | Recovered | ReactionOutcome | CC BY | 34431691 | 20,067,933 | 2021-08-25 |
What was the outcome of reaction 'Viral mutation identified'? | Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit re... | Recovered | ReactionOutcome | CC BY | 34431691 | 20,013,384 | 2021-08-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Angina pectoris'. | Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience.
BACKGROUND
There are limited real-life data on isavuconazole prophylaxis and treatment of invasive mold infections (IMI) in hematological patients and allogeneic hematopoietic cell transplant ... | ISAVUCONAZOLE | DrugsGivenReaction | CC BY | 34432216 | 19,823,727 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash maculo-papular'. | Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience.
BACKGROUND
There are limited real-life data on isavuconazole prophylaxis and treatment of invasive mold infections (IMI) in hematological patients and allogeneic hematopoietic cell transplant ... | ISAVUCONAZOLE | DrugsGivenReaction | CC BY | 34432216 | 19,823,727 | 2021-12 |
What was the administration route of drug 'ISAVUCONAZOLE'? | Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience.
BACKGROUND
There are limited real-life data on isavuconazole prophylaxis and treatment of invasive mold infections (IMI) in hematological patients and allogeneic hematopoietic cell transplant ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34432216 | 19,823,727 | 2021-12 |
What was the dosage of drug 'ISAVUCONAZOLE'? | Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience.
BACKGROUND
There are limited real-life data on isavuconazole prophylaxis and treatment of invasive mold infections (IMI) in hematological patients and allogeneic hematopoietic cell transplant ... | 200 mg (milligrams). | DrugDosage | CC BY | 34432216 | 19,823,727 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | A Rare Case of Acute Fibrinous and Organizing Pneumonia Associated with Systemic Lupus Erythematosus and Autoimmune-associated Hemophagocytic Syndrome: The Involvement of CD163-positive Macrophages.
Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein re... | CYCLOPHOSPHAMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34433711 | 20,660,747 | 2021-08-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | A Rare Case of Acute Fibrinous and Organizing Pneumonia Associated with Systemic Lupus Erythematosus and Autoimmune-associated Hemophagocytic Syndrome: The Involvement of CD163-positive Macrophages.
Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein re... | HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 34433711 | 20,620,170 | 2021-08-24 |
What was the administration route of drug 'CYCLOPHOSPHAMIDE'? | A Rare Case of Acute Fibrinous and Organizing Pneumonia Associated with Systemic Lupus Erythematosus and Autoimmune-associated Hemophagocytic Syndrome: The Involvement of CD163-positive Macrophages.
Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein re... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34433711 | 20,660,747 | 2021-08-24 |
What was the administration route of drug 'HUMAN IMMUNOGLOBULIN G'? | A Rare Case of Acute Fibrinous and Organizing Pneumonia Associated with Systemic Lupus Erythematosus and Autoimmune-associated Hemophagocytic Syndrome: The Involvement of CD163-positive Macrophages.
Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein re... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34433711 | 20,660,747 | 2021-08-24 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | A Rare Case of Acute Fibrinous and Organizing Pneumonia Associated with Systemic Lupus Erythematosus and Autoimmune-associated Hemophagocytic Syndrome: The Involvement of CD163-positive Macrophages.
Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein re... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34433711 | 20,625,907 | 2021-08-24 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | A Rare Case of Acute Fibrinous and Organizing Pneumonia Associated with Systemic Lupus Erythematosus and Autoimmune-associated Hemophagocytic Syndrome: The Involvement of CD163-positive Macrophages.
Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein re... | 750 MG | DrugDosageText | CC BY-NC-ND | 34433711 | 20,660,747 | 2021-08-24 |
What was the dosage of drug 'HUMAN IMMUNOGLOBULIN G'? | A Rare Case of Acute Fibrinous and Organizing Pneumonia Associated with Systemic Lupus Erythematosus and Autoimmune-associated Hemophagocytic Syndrome: The Involvement of CD163-positive Macrophages.
Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein re... | 400 MG/KG DAILY; | DrugDosageText | CC BY-NC-ND | 34433711 | 20,660,747 | 2021-08-24 |
What was the administration route of drug 'HEPARIN SODIUM'? | Spontaneous Muscle Hematoma in Japanese Patients with Severe COVID-19 Treated with Unfractionated Heparin: Two Case Reports.
In hospitalized coronavirus disease 2019 (COVID-19) patients, anticoagulation therapy is administered to prevent thrombosis. However, anticoagulation sometimes causes bleeding complications. We h... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34433713 | 19,975,138 | 2021-11-01 |
What was the outcome of reaction 'Haematoma muscle'? | Spontaneous Muscle Hematoma in Japanese Patients with Severe COVID-19 Treated with Unfractionated Heparin: Two Case Reports.
In hospitalized coronavirus disease 2019 (COVID-19) patients, anticoagulation therapy is administered to prevent thrombosis. However, anticoagulation sometimes causes bleeding complications. We h... | Recovered | ReactionOutcome | CC BY-NC-ND | 34433713 | 19,975,138 | 2021-11-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myoclonic epilepsy and ragged-red fibres'. | Myoclonic Epilepsy with Ragged-red Fibers with Intranuclear Inclusions.
We herein report a case of myoclonic epilepsy with ragged-red fibers (MERRF) harboring a novel variant in mitochondrial cysteine transfer RNA (MT-TC). A 68-year-old woman presented with progressive myoclonic epilepsy with optic atrophy and peripher... | CARBAMAZEPINE, PHENYTOIN | DrugsGivenReaction | CC BY-NC-ND | 34433719 | 20,619,369 | 2021-08-24 |
What was the outcome of reaction 'Myoclonic epilepsy and ragged-red fibres'? | Myoclonic Epilepsy with Ragged-red Fibers with Intranuclear Inclusions.
We herein report a case of myoclonic epilepsy with ragged-red fibers (MERRF) harboring a novel variant in mitochondrial cysteine transfer RNA (MT-TC). A 68-year-old woman presented with progressive myoclonic epilepsy with optic atrophy and peripher... | Recovering | ReactionOutcome | CC BY-NC-ND | 34433719 | 20,619,369 | 2021-08-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Novel LG1 Mutations in Agrin Causing Congenital Myasthenia Syndrome.
The patient had suffered from both proximal and distal limb weakness since her early childhood, without the involvement of ocular or respiratory muscles. Repetitive nerve stimulation (RNS) at 3 Hz showed significant decrement in the area and amplitude... | PYRIDOSTIGMINE | DrugsGivenReaction | CC BY-NC-ND | 34433720 | 20,706,234 | 2021-08-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Congenital myasthenic syndrome'. | Novel LG1 Mutations in Agrin Causing Congenital Myasthenia Syndrome.
The patient had suffered from both proximal and distal limb weakness since her early childhood, without the involvement of ocular or respiratory muscles. Repetitive nerve stimulation (RNS) at 3 Hz showed significant decrement in the area and amplitude... | PYRIDOSTIGMINE | DrugsGivenReaction | CC BY-NC-ND | 34433720 | 20,706,234 | 2021-08-24 |
What was the outcome of reaction 'Condition aggravated'? | Novel LG1 Mutations in Agrin Causing Congenital Myasthenia Syndrome.
The patient had suffered from both proximal and distal limb weakness since her early childhood, without the involvement of ocular or respiratory muscles. Repetitive nerve stimulation (RNS) at 3 Hz showed significant decrement in the area and amplitude... | Recovered | ReactionOutcome | CC BY-NC-ND | 34433720 | 20,706,234 | 2021-08-24 |
What was the outcome of reaction 'Congenital myasthenic syndrome'? | Novel LG1 Mutations in Agrin Causing Congenital Myasthenia Syndrome.
The patient had suffered from both proximal and distal limb weakness since her early childhood, without the involvement of ocular or respiratory muscles. Repetitive nerve stimulation (RNS) at 3 Hz showed significant decrement in the area and amplitude... | Recovered | ReactionOutcome | CC BY-NC-ND | 34433720 | 20,706,234 | 2021-08-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Non-cirrhotic portal hypertension'. | Non-Cirrhotic Portal Hypertension in a Patient With Colonic Carcinoma Treated With Oxaliplatin.
Oxaliplatin is a chemotherapeutic agent with direct toxic action on deoxyribonucleic acid (DNA), which is known to cause an arrest in its synthesis and inducing cell death. It is a crucial medication for colorectal carcinoma... | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 34434437 | 19,810,561 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancytopenia'. | Non-Cirrhotic Portal Hypertension in a Patient With Colonic Carcinoma Treated With Oxaliplatin.
Oxaliplatin is a chemotherapeutic agent with direct toxic action on deoxyribonucleic acid (DNA), which is known to cause an arrest in its synthesis and inducing cell death. It is a crucial medication for colorectal carcinoma... | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 34434437 | 19,810,561 | 2021-03 |
What was the outcome of reaction 'Non-cirrhotic portal hypertension'? | Non-Cirrhotic Portal Hypertension in a Patient With Colonic Carcinoma Treated With Oxaliplatin.
Oxaliplatin is a chemotherapeutic agent with direct toxic action on deoxyribonucleic acid (DNA), which is known to cause an arrest in its synthesis and inducing cell death. It is a crucial medication for colorectal carcinoma... | Recovered | ReactionOutcome | CC BY-NC | 34434437 | 19,810,561 | 2021-03 |
What was the outcome of reaction 'Pancytopenia'? | Non-Cirrhotic Portal Hypertension in a Patient With Colonic Carcinoma Treated With Oxaliplatin.
Oxaliplatin is a chemotherapeutic agent with direct toxic action on deoxyribonucleic acid (DNA), which is known to cause an arrest in its synthesis and inducing cell death. It is a crucial medication for colorectal carcinoma... | Recovered | ReactionOutcome | CC BY-NC | 34434437 | 19,810,561 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal distension'. | A Rare Cause of Abdominal Pain: Intestinal Angioedema.
Angioedema with evidence of mucosal swelling is a rare condition that can be caused by angiotensin-converting enzyme inhibitors. The authors describe a case of a 28-year-old woman medicated with lisinopril 2 months before, with abdominal pain associated with nausea... | LISINOPRIL | DrugsGivenReaction | CC BY-NC | 34434446 | 20,085,080 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal pain'. | A Rare Cause of Abdominal Pain: Intestinal Angioedema.
Angioedema with evidence of mucosal swelling is a rare condition that can be caused by angiotensin-converting enzyme inhibitors. The authors describe a case of a 28-year-old woman medicated with lisinopril 2 months before, with abdominal pain associated with nausea... | LISINOPRIL | DrugsGivenReaction | CC BY-NC | 34434446 | 20,085,080 | 2021-04 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.